These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 8296092

  • 21. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM.
    Clin Infect Dis; 2016 Jun 01; 62(11):1329-1335. PubMed ID: 27001804
    [Abstract] [Full Text] [Related]

  • 22. Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects.
    Cryz SJ, Kaper J, Tacket C, Nataro J, Levine MM.
    Dev Biol Stand; 1995 Jun 01; 84():237-44. PubMed ID: 7796960
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
    Taylor DN, Tacket CO, Losonsky G, Castro O, Gutierrez J, Meza R, Nataro JP, Kaper JB, Wasserman SS, Edelman R, Levine MM, Cryz SJ.
    Infect Immun; 1997 Sep 01; 65(9):3852-6. PubMed ID: 9284163
    [Abstract] [Full Text] [Related]

  • 24. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.
    Lagos R, Avendaño A, Prado V, Horwitz I, Wasserman S, Losonsky G, Cryz S, Kaper JB, Levine MM.
    Infect Immun; 1995 Feb 01; 63(2):707-9. PubMed ID: 7822046
    [Abstract] [Full Text] [Related]

  • 25. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.
    Chowdhury MI, Sheikh A, Qadri F.
    Expert Rev Vaccines; 2009 Dec 01; 8(12):1643-52. PubMed ID: 19943759
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
    Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F.
    Vaccine; 2011 Oct 26; 29(46):8285-92. PubMed ID: 21907255
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M.
    Expert Rev Vaccines; 2017 Mar 26; 16(3):197-213. PubMed ID: 28165831
    [Abstract] [Full Text] [Related]

  • 31. Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine.
    Jackson SS, Chen WH.
    Future Microbiol; 2015 Mar 26; 10(8):1271-81. PubMed ID: 26228388
    [Abstract] [Full Text] [Related]

  • 32. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, Hung NV, Canh DG, Thiem VD, Naficy A, Ivanoff B, Svennerholm AM, Holmgren J, Clemens JD.
    Bull World Health Organ; 2002 Mar 26; 80(1):2-8. PubMed ID: 11884967
    [Abstract] [Full Text] [Related]

  • 33. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.
    Cryz SJ, Que JU, Levine MM, Wiedermann G, Kollaritsch H.
    Infect Immun; 1995 Apr 26; 63(4):1336-9. PubMed ID: 7890391
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants.
    Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, Saha A, Al Tarique A, Seidlein LV, Park E, Killeen KP, Mekalanos JJ, Clemens JD, Sack DA, PXV Study Group.
    Vaccine; 2007 Jan 04; 25(2):231-8. PubMed ID: 16996172
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR.
    Cooper PJ, Chico ME, Losonsky G, Sandoval C, Espinel I, Sridhara R, Aguilar M, Guevara A, Guderian RH, Levine MM, Griffin GE, Nutman TB.
    J Infect Dis; 2000 Oct 04; 182(4):1199-206. PubMed ID: 10979918
    [Abstract] [Full Text] [Related]

  • 40. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.
    Kollaritsch H, Furer E, Herzog C, Wiedermann G, Que JU, Cryz SJ.
    Infect Immun; 1996 Apr 04; 64(4):1454-7. PubMed ID: 8606118
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.